Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1501 + BCG vs Placebo + BCG in High-risk BCG-naive Papillary-Only NMIBC
NCT07726992Phase 3Recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Aug 2026
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
A Phase 3 trial of SHR-1501 in non-muscle-invasive bladder cancer (NMIBC), sponsored by Suzhou Suncadia Biopharmaceutical. Started Aug 2026; status: recruiting.
02
Drugs
SHR-1501
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT07726992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07726992.